Home>>Signaling Pathways>> Proteases>> Drug Metabolite>>N-Acetylprocainamide (Acecainide)

N-Acetylprocainamide (Acecainide)

Catalog No.GC34027

N-Acetylprocainamide (Acecainide) is a class III antiarrhythmic, which blocks K+ channels.

Products are for research use only. Not for human use. We do not sell to patients.

N-Acetylprocainamide (Acecainide) Chemical Structure

Cas No.: 32795-44-1

Size Price Stock Qty
10mM (in 1mL DMSO)
$50.00
In stock
100mg
$46.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

N-Acetylprocainamide is a class III antiarrhythmic, which blocks K+ channels.

N-Acetylprocainamide is a K+ blocker. N-Acetylprocainamide decreases the tensions induced by K+ and methacholine. The pIC50 values for N-acetylprocainamide against the contractions induced by 0.3 and 1 μM methacholine are 2.80 ± 0.03 and 2.65 ± 0.02, respectively. And such a relaxant effect of N-Acetylprocainamide is inhibited by K+ channel blockers[1]. N-Acetylprocainamide shows no effect on Na+ absorption or Cl- secretion[2].

[1]. Nakahara T, et al. Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle. Eur J Pharmacol. 2001 Mar 9;415(1):73-8. [2]. Plass H, et al. Class I antiarrhythmics inhibit Na+ absorption and Cl- secretion in rabbit descending colon epithelium. Naunyn Schmiedebergs Arch Pharmacol. 2005 Jun;371(6):492-9.

Reviews

Review for N-Acetylprocainamide (Acecainide)

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for N-Acetylprocainamide (Acecainide)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.